HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $16,309,421 | +5.7% | 426,940 | -0.2% | 0.01% | +10.0% |
Q2 2023 | $15,436,914 | -5.6% | 427,971 | -0.0% | 0.01% | -9.1% |
Q1 2023 | $16,346,825 | -55.4% | 428,064 | -33.5% | 0.01% | -57.7% |
Q4 2022 | $36,651,336 | +34.3% | 644,142 | -53.3% | 0.03% | +30.0% |
Q3 2022 | $27,292,265 | -9.8% | 1,379,072 | +100.4% | 0.02% | -4.8% |
Q2 2022 | $30,274,000 | +4.0% | 688,040 | -5.7% | 0.02% | +50.0% |
Q1 2022 | $29,103,000 | +7.8% | 729,775 | +8.7% | 0.01% | +27.3% |
Q4 2021 | $27,004,000 | +0.8% | 671,571 | +2.0% | 0.01% | -8.3% |
Q3 2021 | $26,784,000 | -9.5% | 658,395 | +1.0% | 0.01% | -7.7% |
Q2 2021 | $29,601,000 | +3.9% | 651,856 | -4.6% | 0.01% | 0.0% |
Q1 2021 | $28,481,000 | -16.6% | 683,169 | -14.5% | 0.01% | -18.8% |
Q4 2020 | $34,143,000 | +46.1% | 799,410 | -10.1% | 0.02% | +33.3% |
Q3 2020 | $23,371,000 | – | 889,303 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SNYDER CAPITAL MANAGEMENT L P | 4,324,232 | $165,185,662 | 3.73% |
Steamboat Capital Partners, LLC | 196,898 | $7,521,504 | 2.79% |
2Xideas AG | 600,799 | $22,950,522 | 2.54% |
BERNZOTT CAPITAL ADVISORS | 171,808 | $6,563,066 | 2.26% |
Redwood Investments, LLC | 328,459 | $12,547,134 | 1.70% |
Mesirow Institutional Investment Management, Inc. | 380,415 | $14,531,853 | 1.47% |
Granite Investment Partners, LLC | 856,253 | $32,708,865 | 1.37% |
Penn Capital Management Company, LLC | 324,707 | $12,453,211 | 1.28% |
EFG Asset Management (North America) Corp. | 137,739 | $5,262,319 | 1.25% |
First Light Asset Management, LLC | 313,536 | $11,977,075 | 1.14% |